06/06/2026
"As the most common form of dementia, Alzheimer’s accounts for between 60 and 80 percent of all diagnosed cases in the world. The disease stems from the loss of neurons in the brain, causing irreversible impairment in memory and thinking.
Due to the complex nature of Alzheimer’s disease, researchers are still uncovering what role the endocannabinoid system plays in both the treatment and causation. However, growing evidence shows the ECS, or lack of endocannabinoids, plays a role in the creation of the disease itself.
Various types of signaling occur in our brain, and the dysfunction of the ECS due to Clinical Endocannabinoid Deficiency Syndrome is thought to be a leading cause of issues like Alzheimer's.
The loss of nerve cell connection in Dementia patients results in plaque accumulation and variable nerve cell transmission. These disruptions essentially prevent the receptors found within the ECS from keeping the body in homeostasis which furthers the complications.
CB1 receptors are a vital component of the endocannabinoid system as they're responsible for neurotransmission behavior. These receptors are commonly found in regions of the brain that CBD stimulates to produce their intended effect. Research has found with Alzheimer’s disease, CBD mainly targets the CB1 receptors to produce a favorable immune response.
CBD is also widely known for its anti-inflammatory response within our immune system which promotes neurogenesis and lessens neuroinflammatory responses. Neurogenesis is crucial for Alzheimer's patients because the growth and development of new nervous tissue can prevent further memory impairment and loss of cognitive abilities." -Mike Robinson, founder Global Cannabinoid Research Center
